Skip to content

US · SYK · MEDICAL - DEVICES

Stryker Corporation (SYK) intrinsic value and stock valuation

$310.00as of 2026-11-21 · Mkt cap 129.2B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Stryker Corporation DCF and intrinsic value

InvestorsCraft values SYK with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from SYK’s statements →

Stryker Corporation Graham Number

Graham Number: $105.87d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Portage, MI 49002 stryker.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$25.1B+11.8% 5y CAGRd
20112025
Net income
$3.25B+15.2% 5y CAGRd
20112025
Free cash flow
$4.28B+9% 5y CAGRd
20112025
Total equity
$22.4B+11.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$25.1B$22.6B$20.5B$18.4B$17.1B
Operating income$4.89B$5.06B$4.28B$3.73B$3.76B
Net income$3.25B$2.99B$3.17B$2.36B$1.99B
EPSd$8.49M$7.76M$8.25M$6.17M$5.22M
Operating cash flow$5.04B$4.24B$3.71B$2.62B$3.26B
Capital expenditure-$-761M-$-755M-$-575M-$-588M-$-525M
Free cash flow$4.28B$3.49B$3.14B$2.04B$2.74B
Total assets$47.8B$43B$39.9B$36.9B$34.6B
Total debt$16.4B$14.1B$13.5B$13.5B$12.9B
Net debt$12.3B$10.5B$10.5B$11.7B$9.96B
Total equity$22.4B$20.6B$18.6B$16.6B$14.9B
Cash and short-term investments$4.1B$4.49B$3.05B$1.93B$3.02B
Income statement
20252024202320222021
Revenue$25.1B$22.6B$20.5B$18.4B$17.1B
Cost of revenue$9.05B$8.62B$8B$7.41B$6.4B
Gross profit$16.1B$14B$12.5B$11B$10.7B
Research and development expenses$1.58B$1.41B$1.29B$1.23B$1.13B
Selling, general and administrative expenses$8.65B$7.51B$6.92B$6.08B$5.81B
Other expenses$902M$0.00$0.00$0.00$0.00
Operating expenses$11.2B$8.92B$8.21B$7.31B$6.95B
Cost and expenses$20.2B$17.5B$16.2B$14.7B$13.3B
Interest income$121M$139M$75M$94M$68M
Interest expense$607M$396M$356M$337M$337M
Depreciation and amortization$1.19B$1.05B$1.03B$998M$990M
Ebitda$6.31B$4.94B$5.06B$4.02B$3.61B
Operating income$4.89B$5.06B$4.28B$3.73B$3.76B
Total other income/expenses, net-$-375M-$-1.57B-$-608M-$-1.05B-$-1.48B
Income before tax$4.51B$3.49B$3.67B$2.68B$2.28B
Income tax expense$1.27B$499M$508M$325M$287M
Net income$3.25B$2.99B$3.17B$2.36B$1.99B
Weighted average shares outstanding$382.2M$381M$379.6M$378.2M$377M
Weighted average diluted shares outstanding$382.2M$385.6M$383.7M$382.2M$382.3M
Balance sheet
20252024202320222021
Cash and short-term investments$4.1B$4.49B$3.05B$1.93B$3.02B
Net receivables$4.04B$3.99B$3.77B$3.57B$3.02B
Inventory$5.31B$4.77B$4.84B$4B$3.31B
Total current assets$14.8B$14.8B$12.5B$10.3B$10B
Property, plant and equipment, net$4.4B$3.96B$3.71B$3.44B$3.25B
Goodwill and intangible assets$25B$20.3B$19.8B$19.8B$17.8B
Long-term investments$2M$39M$2M$90M$66M
Total non-current assets$33.1B$28.1B$27.4B$26.6B$24.6B
Total assets$47.8B$43B$39.9B$36.9B$34.6B
Accounts payable$1.8B$1.68B$1.52B$1.41B$1.13B
Short-term debt$1.15B$1.55B$2.24B$1.31B$119M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.79B$7.62B$7.92B$6.3B$4.55B
Long-term debt$15.2B$12.6B$11.3B$12.2B$12.8B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$17.6B$14.7B$13.4B$14B$15.2B
Capital lease obligations$348M$379M$356M$357M$310M
Total liabilities$25.4B$22.3B$21.3B$20.3B$19.8B
Common stock$38M$38M$38M$38M$38M
Retained earnings$20.5B$18.5B$16.8B$14.8B$13.5B
Accumulated other comprehensive income (loss)-$-687M-$-293M-$-416M-$-221M-$-531M
Total equity$22.4B$20.6B$18.6B$16.6B$14.9B
Total investments$91M$880M$84M$174M$141M
Total debt$16.4B$14.1B$13.5B$13.5B$12.9B
Net debt$12.3B$10.5B$10.5B$11.7B$9.96B
Cash flow statement
20252024202320222021
Net income$3.25B$2.99B$3.17B$2.36B$1.99B
Depreciation and amortization$1.19B$1.05B$1.03B$998M$990M
Stock-based compensation$243M$229M$205M$168M$171M
Change in working capital-$-373M-$-683M-$-500M-$-732M$279M
Accounts receivable$127M-$-321M-$-175M-$-579M-$-377M
Inventory-$-297M-$-206M-$-797M-$-762M-$-189M
Accounts payable$94M$192M$77M$290M$329M
Net cash provided by operating activities$5.04B$4.24B$3.71B$2.62B$3.26B
Investments in property, plant and equipment-$-761M-$-755M-$-575M-$-588M-$-525M
Acquisitions, net-$-4.8B-$-1.63B-$-390M-$-2.56B-$-339M
Net cash used for investing activities-$-4.87B-$-3B-$-962M-$-2.92B-$-859M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-149M-$-195M-$-155M-$-122M-$-114M
Dividends paid-$-1.28B-$-1.22B-$-1.14B-$-1.05B-$-950M
Net cash used for financing activities$113M-$-525M-$-1.59B-$-749M-$-2.37B
Net change in cash$359M$681M$1.13B-$-1.1B$1M
Cash at end of period$4.01B$3.65B$2.97B$1.84B$2.94B
Operating cash flow$5.04B$4.24B$3.71B$2.62B$3.26B
Capital expenditure-$-761M-$-755M-$-575M-$-588M-$-525M
Free cash flow$4.28B$3.49B$3.14B$2.04B$2.74B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Stryker Corporation

        Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

        CEO
        Kevin A. Lobo
        Employees
        56K
        Beta
        0.78

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Stryker Corporation (SYK)?

        Stryker Corporation (SYK) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SYK undervalued?

        SYK trades at a price of $310.00 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.